• Something wrong with this record ?

Germline transgenesis in rabbits by pronuclear microinjection of Sleeping Beauty transposons

Z. Ivics, L. Hiripi, OI. Hoffmann, L. Mátés, TY. Yau, S. Bashir, V. Zidek, V. Landa, A. Geurts, M. Pravenec, T. Rülicke, Z. Bösze, Z. Izsvák,

. 2014 ; 9 (4) : 794-809.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15023542
E-resources Online Full text

NLK ProQuest Central from 2006-06-01 to 1 year ago
Medline Complete (EBSCOhost) from 2013-03-01 to 2015-12-31
Health & Medicine (ProQuest) from 2006-06-01 to 1 year ago

Links

PubMed 24625779
DOI 10.1038/nprot.2014.009
Knihovny.cz E-resources

The laboratory rabbit (Oryctolagus cuniculus) is widely used as a model for a variety of inherited and acquired human diseases. In addition, the rabbit is the smallest livestock animal that is used to transgenically produce pharmaceutical proteins in its milk. Here we describe a protocol for high-efficiency germline transgenesis and sustained transgene expression in rabbits by using the Sleeping Beauty (SB) transposon system. The protocol is based on co-injection into the pronuclei of fertilized oocytes of synthetic mRNA encoding the SB100X hyperactive transposase together with plasmid DNA carrying a transgene construct flanked by binding sites for the transposase. The translation of the transposase mRNA is followed by enzyme-mediated excision of the transgene cassette from the plasmids and its permanent genomic insertion to produce stable transgenic animals. Generation of a germline-transgenic founder animal by using this protocol takes ∼2 months. Transposon-mediated transgenesis compares favorably in terms of both efficiency and reliable transgene expression with classic pronuclear microinjection, and it offers comparable efficacies (numbers of transgenic founders obtained per injected embryo) to lentiviral approaches, without limitations on vector design, issues of transgene silencing, and the toxicity and biosafety concerns of working with viral vectors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023542
003      
CZ-PrNML
005      
20150727112533.0
007      
ta
008      
150709s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/nprot.2014.009 $2 doi
035    __
$a (PubMed)24625779
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Ivics, Zoltán $u Division of Medical Biotechnology, Paul Ehrlich Institute, Langen, Germany.
245    10
$a Germline transgenesis in rabbits by pronuclear microinjection of Sleeping Beauty transposons / $c Z. Ivics, L. Hiripi, OI. Hoffmann, L. Mátés, TY. Yau, S. Bashir, V. Zidek, V. Landa, A. Geurts, M. Pravenec, T. Rülicke, Z. Bösze, Z. Izsvák,
520    9_
$a The laboratory rabbit (Oryctolagus cuniculus) is widely used as a model for a variety of inherited and acquired human diseases. In addition, the rabbit is the smallest livestock animal that is used to transgenically produce pharmaceutical proteins in its milk. Here we describe a protocol for high-efficiency germline transgenesis and sustained transgene expression in rabbits by using the Sleeping Beauty (SB) transposon system. The protocol is based on co-injection into the pronuclei of fertilized oocytes of synthetic mRNA encoding the SB100X hyperactive transposase together with plasmid DNA carrying a transgene construct flanked by binding sites for the transposase. The translation of the transposase mRNA is followed by enzyme-mediated excision of the transgene cassette from the plasmids and its permanent genomic insertion to produce stable transgenic animals. Generation of a germline-transgenic founder animal by using this protocol takes ∼2 months. Transposon-mediated transgenesis compares favorably in terms of both efficiency and reliable transgene expression with classic pronuclear microinjection, and it offers comparable efficacies (numbers of transgenic founders obtained per injected embryo) to lentiviral approaches, without limitations on vector design, issues of transgene silencing, and the toxicity and biosafety concerns of working with viral vectors.
650    _2
$a zvířata $7 D000818
650    12
$a geneticky modifikovaná zvířata $7 D030801
650    12
$a transpozibilní elementy DNA $7 D004251
650    _2
$a ženské pohlaví $7 D005260
650    12
$a technika přenosu genů $7 D018014
650    _2
$a zárodečné buňky $7 D005854
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikroinjekce $7 D008845
650    _2
$a králíci $7 D011817
650    _2
$a časové faktory $7 D013997
650    _2
$a transposasy $x genetika $7 D019895
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hiripi, László $u Agricultural Biotechnology Center, Gödöllö, Hungary.
700    1_
$a Hoffmann, Orsolya I $u Agricultural Biotechnology Center, Gödöllö, Hungary.
700    1_
$a Mátés, Lajos $u Biological Research Centre, Hungarian Academy of Sciences, Szeged, Hungary.
700    1_
$a Yau, Tien Yin $u Institute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Vienna, Austria.
700    1_
$a Bashir, Sanum $u Max Delbrück Center for Molecular Medicine, Berlin, Germany.
700    1_
$a Zidek, Vaclav $u Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Landa, Vladimír $u Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Geurts, Aron $u Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
700    1_
$a Pravenec, Michal $u Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
700    1_
$a Rülicke, Thomas $u Institute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Vienna, Austria.
700    1_
$a Bösze, Zsuzsanna $u Agricultural Biotechnology Center, Gödöllö, Hungary.
700    1_
$a Izsvák, Zsuzsanna $u Max Delbrück Center for Molecular Medicine, Berlin, Germany.
773    0_
$w MED00159607 $t Nature protocols $x 1750-2799 $g Roč. 9, č. 4 (2014), s. 794-809
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24625779 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150727112617 $b ABA008
999    __
$a ok $b bmc $g 1083879 $s 906535
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 9 $c 4 $d 794-809 $i 1750-2799 $m Nature protocols $n Nat Protoc $x MED00159607
LZP    __
$a Pubmed-20150709

Find record

Citation metrics

Archiving options